Teva Pharmaceutical Industries Ltd. $TEVA is Avidity Partners Management LP’s 5th Largest Position

Avidity Partners Management LP decreased its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 18.2% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 417,300 shares of the company’s stock after selling 92,700 shares during the period. Teva Pharmaceutical Industries accounts for 3.8% of Avidity Partners Management LP’s portfolio, making the stock its 5th largest position. Avidity Partners Management LP’s holdings in Teva Pharmaceutical Industries were worth $13,024,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Allworth Financial LP grew its stake in shares of Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after buying an additional 329 shares during the last quarter. Grove Bank & Trust grew its stake in shares of Teva Pharmaceutical Industries by 300.0% during the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after buying an additional 750 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Teva Pharmaceutical Industries by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after buying an additional 345 shares during the last quarter. Global Retirement Partners LLC grew its stake in shares of Teva Pharmaceutical Industries by 27.3% during the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after buying an additional 292 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its stake in shares of Teva Pharmaceutical Industries by 567.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,334 shares of the company’s stock valued at $42,000 after buying an additional 1,134 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock opened at $34.58 on Friday. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. The company has a market capitalization of $39.75 billion, a P/E ratio of 26.00, a P/E/G ratio of 3.53 and a beta of 0.84. The company’s 50-day simple moving average is $33.28 and its two-hundred day simple moving average is $31.96. Teva Pharmaceutical Industries Ltd. has a one year low of $14.99 and a one year high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The business had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. As a group, equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.36 EPS for the current year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 144,180 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $34.99, for a total value of $5,044,858.20. Following the transaction, the insider directly owned 80,760 shares in the company, valued at $2,825,792.40. This represents a 64.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Amir Weiss sold 10,679 shares of the company’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total transaction of $384,444.00. Following the completion of the transaction, the chief accounting officer owned 20,016 shares in the company, valued at $720,576. This represents a 34.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 421,470 shares of company stock worth $14,570,945. 0.54% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research firms have recently commented on TEVA. Barclays upped their target price on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Bank of America upped their target price on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. UBS Group upped their target price on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Wall Street Zen raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. Finally, Piper Sandler restated an “overweight” rating and issued a $42.00 target price (up from $41.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, April 30th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $41.78.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.